Abivax unveils its Q1 2026 results and progress on Study 108

On May 22, 2026, Abivax released its first-quarter financial results and data from Study 108 regarding obefazimod. The intention-to-treat (ITT) analysis of the study revealed sustained clinical remission in patients with ulcerative colitis (UC). After two to four years of treatment at 50 mg, the dose was reduced to 25 mg, and by week 144, 68% of patients were in remission.

Financially, Abivax had €491.6 million in cash as of March 31, 2026, ensuring financial visibility until the end of 2027. R&D expenses increased, primarily for the combination therapy of obefazimod. General expenses decreased, attributed to lower personnel costs.